# Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

**Authors:** Anja Charlotte Lundgren Mortensen, Hanna Berglund, Mehran Hariri, Eleftherios Papalanis, Christer Malmberg, Diana Spiegelberg

PMC · DOI: 10.1038/s41598-025-13541-y · Scientific Reports · 2025-07-29

## Full-text entities

- **Genes:** HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}
- **Diseases:** thyroid cancer (MESH:D013964)
- **Chemicals:** sorafenib (MESH:D000077157), BHT-101 (-), onalespib (MESH:C552103)
- **Cell lines:** SW1736 — Homo sapiens (Human), Thyroid gland anaplastic carcinoma, Cancer cell line (CVCL_3883), 8305C — Homo sapiens (Human), Thyroid gland anaplastic carcinoma, Cancer cell line (CVCL_1053), MDA-T32 — Homo sapiens (Human), Thyroid gland papillary carcinoma, Cancer cell line (CVCL_W913), BHT-101 — Homo sapiens (Human), Thyroid gland anaplastic carcinoma, Cancer cell line (CVCL_1085)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12307577/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12307577/full.md

---
Source: https://tomesphere.com/paper/PMC12307577